These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 18274990)

  • 1. Can iron chelators influence the progression of atherosclerosis?
    Marx JJ; Kartikasari AE; Georgiou NA
    Hemoglobin; 2008; 32(1-2):123-34. PubMed ID: 18274990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recognition and treatment of iron overload.
    Brown EB
    Adv Intern Med; 1980; 26():159-86. PubMed ID: 7013439
    [No Abstract]   [Full Text] [Related]  

  • 3. Removal of non-transferrin-bound iron from blood with iron overload using a device with immobilized desferrioxamine.
    Ambrus CM; Stadler I; Toumbis CA; Stadler A; Anthone S; Anthone R; DeAlarcon P; Deshpande G; Conway J; Vladutiu AO; Ambrus JL
    J Med; 1999; 30(3-4):211-24. PubMed ID: 17312675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantification of non-transferrin-bound iron in the presence of unsaturated transferrin.
    Gosriwatana I; Loreal O; Lu S; Brissot P; Porter J; Hider RC
    Anal Biochem; 1999 Sep; 273(2):212-20. PubMed ID: 10469492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LPI-labile plasma iron in iron overload.
    Cabantchik ZI; Breuer W; Zanninelli G; Cianciulli P
    Best Pract Res Clin Haematol; 2005 Jun; 18(2):277-87. PubMed ID: 15737890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-transferrin bound iron in Thalassemia: differential detection of redox active forms in children and older patients.
    Breuer W; Ghoti H; Shattat A; Goldfarb A; Koren A; Levin C; Rachmilewitz E; Cabantchik ZI
    Am J Hematol; 2012 Jan; 87(1):55-61. PubMed ID: 22125177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High nontransferrin bound iron levels and heart disease in thalassemia major.
    Piga A; Longo F; Duca L; Roggero S; Vinciguerra T; Calabrese R; Hershko C; Cappellini MD
    Am J Hematol; 2009 Jan; 84(1):29-33. PubMed ID: 19006228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of antioxidants and iron chelators in the treatment of oxidative stress in thalassemia.
    Fibach E; Rachmilewitz EA
    Ann N Y Acad Sci; 2010 Aug; 1202():10-6. PubMed ID: 20712766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Labile plasma iron in iron overload: redox activity and susceptibility to chelation.
    Esposito BP; Breuer W; Sirankapracha P; Pootrakul P; Hershko C; Cabantchik ZI
    Blood; 2003 Oct; 102(7):2670-7. PubMed ID: 12805056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iron chelators for the treatment of iron overload disease: relationship between structure, redox activity, and toxicity.
    Chaston TB; Richardson DR
    Am J Hematol; 2003 Jul; 73(3):200-10. PubMed ID: 12827659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Iron metabolism and its exploration in clinical biology].
    Brissot P; Pigeon C; Moirand R; Guyader D; Mendler MH; Sapey T; Deugnier Y; Lescoat G; Loréal O
    Ann Biol Clin (Paris); 1998 Jul; 56 Spec No():5-10. PubMed ID: 9827209
    [No Abstract]   [Full Text] [Related]  

  • 12. Iron overload.
    Halliday JW; Powell LW
    Semin Hematol; 1982 Jan; 19(1):42-53. PubMed ID: 6763338
    [No Abstract]   [Full Text] [Related]  

  • 13. Role of iron in osteoporosis.
    Weinberg ED
    Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():81-5. PubMed ID: 19337160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic potential of iron chelators in diseases associated with iron mismanagement.
    Weinberg ED
    J Pharm Pharmacol; 2006 May; 58(5):575-84. PubMed ID: 16640825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endothelial activation and induction of monocyte adhesion by nontransferrin-bound iron present in human sera.
    Kartikasari AE; Georgiou NA; Visseren FL; van Kats-Renaud H; van Asbeck BS; Marx JJ
    FASEB J; 2006 Feb; 20(2):353-5. PubMed ID: 16368718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thalassemia: cardiac iron and chelators.
    Gaur A
    Indian Pediatr; 2012 Apr; 49(4):268-9. PubMed ID: 22565070
    [No Abstract]   [Full Text] [Related]  

  • 17. Interplay between superoxide and nitric oxide in thalassemia and Fanconi's anemia.
    Afanas'ev IB
    Hemoglobin; 2006; 30(1):113-8. PubMed ID: 16540423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of iron overload in thalassemia.
    Cianciulli P
    Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():208-13. PubMed ID: 19337180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-transferrin bound iron: a key role in iron overload and iron toxicity.
    Brissot P; Ropert M; Le Lan C; Loréal O
    Biochim Biophys Acta; 2012 Mar; 1820(3):403-10. PubMed ID: 21855608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-transferrin-bound iron transporters.
    Knutson MD
    Free Radic Biol Med; 2019 Mar; 133():101-111. PubMed ID: 30316781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.